Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Mike K who wrote (336)	9/2/1999 11:01:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

Hi Mike: Surely hope and wish that You successfully defeat MM and that T therapy will help. Are you currently on T monotherapy? <<''This study supports prior observations of thalidomide's efficacy in multiple myeloma, but also highlights its therapeutic benefit at low, well- tolerated dosages,' said Dr. Durie. ''Lower doses of thalidomide mean less side effects and will allow more patients to remain on therapy longer and thus receive the full benefit of this remarkable drug.'>> Seams that lower T dose (like yours, 200-400 mg/day) is as good as high dose (800-1600mg/day), so CHOP combination, if tolerable, (I am looking forward to hear results from this trial, by year-end) will be logical approach for healthy person newly diagnosed with MM. CELG is doing good progress with T development, and (+)-R results may be another nice surprise (I mean positive one). Cheers, and God be with you. Miljenko